Prostate Stereotactic ablative body radiotherapy (SABR) is an established technique that delivers radiation in a non-invasive approach for men with prostate cancer. The treatment regimen is given in total of 5 fractions with one treatment per day at every other day or weekly sessions. Ultra-hypofractionated radiotherapy (UHRT) is an emerging monotherapy for localized prostate cancer however, several trials have observed demonstrating superior biochemical control of a two-fraction (HDR) over single-fraction approach. The study aims to compare an experimental shorter course of prostate ultra-hypofractionated radiotherapy (UHRT) that will deliver what is expected to be an equivalent amount of radiation as given in the standard 5 treatment regimen. UHRT is given in 2 treatments with one treatment a week for 2 consecutive weeks.
Histologically confirmed prostate adenocarcinoma (centrally reviewed)
Low risk - T1-T2b, grade group 1, AND PSA < 10 ng/ml;
Favorable risk
Only one of the following intermediate risk factors - cT2c, grade group 2, or PSA 10-20 ng/ml; or
Androgen deprivation therapy (LHRH-agonists or antiandrogens) given or planned
Prior pelvic radiotherapy
Anticoagulation medication (if unsafe to discontinue for gold seed insertion)
Diagnosis of bleeding diathesis
Sunnybrook Health Sciences Centre
Lead sponsor
Prostate Cure Foundation
Collaborator